Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 8/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DBH | P09172 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137812 | 0.89 | SMN1; SMN2 (0.41) | FFAR1PKMSMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL10137811 | 0.87 | FFAR1 (0.40) | FFAR1PKMSMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL17678836 | 0.87 | TAS1R3 (0.52) | FFAR1PKMSMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL10137813 | 0.85 | SMN1; SMN2 (0.42) | FFAR1PKMSMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL10654634 | 0.85 | FFAR1 (0.39) | FFAR1PKMSMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL19734346 | 0.82 | KMT2A (0.40) | FFAR1PKMSMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL14189053 | 0.77 | SMN1; SMN2 (0.39) | PKMSMN1; SMN2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL24624146 | 0.76 | PKM (0.33) | FFAR1PKMSMN1; SMN2 | |
| SCHEMBL20508995 | 0.74 | CES2 (0.39) | PKMSMN1; SMN2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14519935 | 0.74 | FFAR1 (0.42) | FFAR1CES2CES1RECQLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673130-B2 | Catalyst system containing a metathesis catalyst and at least one phenolic compound and a process for metathesis of nitrile-butadiene rubber (NBR) using the catalyst system | ARLANXEO DEUTSCHLAND GMBH (DE) | 2023-06-13 | — | — | US | disclosed |
| EP-2598511-B1 | NOVEL STABLE AND HIGHLY TUNABLE METATHESIS CATALYSTS | ECOLE NAT SUPERIEURE DE CHIMIE DE RENNES (FR) | 2018-07-04 | — | — | EP | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | FFAR1 4563/4885PKM 3364/4885SMN1; SMN2 3286/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | FFAR1 4563/4885PKM 3364/4885SMN1; SMN2 3286/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | FFAR1 4563/4885PKM 3364/4885SMN1; SMN2 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.